Search Results

You are looking at 1 - 10 of 32 items for :

  • "polychemotherapy" x
Clear All
Full access

Mary Cianfrocca and William J. Gradishar

The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.

Full access

Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes and Fernando Rivera

registry comprises adult patients (aged ≥18 years) with pathologically confirmed, unresectable, or metastatic gastric, gastroesophageal junction, or distal esophageal adenocarcinoma, who received at least one cycle of polychemotherapy. Exclusion criteria

Full access

Charles L. Loprinzi and Peter M. Ravdin

instrument . J Clin Oncol 1995 ; 13 : 847 – 853 . 4 Cole BF Gelber RD Gelber S . Polychemotherapy for early breast cancer: An overview of the randomized clinical trials with quality-adjusted survival analysis . Lancet 2001 ; 358 : 277 – 286

Full access

Rodger J. Winn

; 317 : 771 – 775 . 22 Souquet PJ Chauvin F Boissel JP . Polychemotherapy in advanced non-small-ling cancer: A meta-analysis . Lancet 1993 ; 342 ; 19 – 21 . 23 NCCN Non-Small-Cell Ling Cancer Guideline, v1.2004. Available at

Full access

Gayathri Nagaraj and Cynthia X. Ma

literature. Although the proportional risk reduction from adjuvant polychemotherapy was found to be independent of ER status and tamoxifen use in the Oxford overview, 3 the relative chemoresistance of ER+ disease has been demonstrated in the neoadjuvant

Full access

Donna Trauth and Lori J. Goldstein

hormonal, cytotoxic or immune therapy. 133 Randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women . Lancet 1992 ; 339 : 71 – 85 . 4 Early Breast Cancer Trialists' Collaborative Group . Polychemotherapy for early

Full access

S. Machele Donat

. J Urol 1996 ; 155 : 495 – 499 . 42 Stöckle M Meyenburg W Wellek S . Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further

Full access

William C. Huang and Bernard H. Bochner

following cystectomy for invasive bladder cancer: a prospective comparative trial . J Urol 1991 ; 145 : 459 – 464 ; discussion 464–467 . 23. Stockle M Meyenburg W Wellek S . Adjuvant polychemotherapy of nonorgan-confined bladder cancer after

Full access

Jeffrey Allen and Mohammad Jahanzeb

Edited by Kerrin G. Robinson

trial and update of systematic review . Lancet 2007 ; 369 : 1929 – 1937 . 27. Dautzenberg B Benichou J Allard P . Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma. Results

Full access

Letizia Gandolfi, Sarah Adamo, Alessandro Pileri, Alessandro Broccoli, Lisa Argnani and Pier Luigi Zinzani

mastoid and sella turcica regions after a few months, the patient was then treated with a polychemotherapy regimen (MACOP-B) and experienced a partial response. She remained clinically stable until 2005, when a PET scan showed a skeletal recurrence (ilium